查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1224660

CRO 体内肿瘤学市场规模、份额和趋势分析报告：按适应症（血液癌、实体瘤）、地区、细分市场预测，2023-2030 年

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

CRO体内肿瘤市场的发展与趋势

根据 Grand View Research, Inc. 的最新报告，全球 CRO 肿瘤体内市场规模预计到 2030 年将达到 23 亿美元，从 2023 年到 2030 年的复合年增长率为 8.2%。 研发活动外包的增加、对先进药物的高需求以及 CRO 对国际标准的采用是推动市场增长的主要因素。

此外，专利到期带来的竞争加剧、仿製药的快速增长以及生物仿製药的引入等压力促使製药公司寻求这些组织的支持。 因此，可以预见，在预测期内，以癌症为基础的体内CRO行业很可能会呈现出利润丰厚的增长态势。

技术进步，例如用于市场进入者招募和交流的移动创新、基于网络的生命科学实验室以及执行常规测试的机器人实验室，可以带来市场机会。 在全球范围内，外包是希望进入新市场的讚助商和製药公司的一种解决方案。 辉瑞和葛兰素史克等大型製药公司已与当地的 CMO 和 CRO 合作，帮助外国公司在新兴市场实现其营销、监管和製造目标，并取得了成功。

此外，该行业不断增加的合併和合作预计将在未来几年扩大市场。 例如，2023 年 1 月，分析解决方案公司 Bruker 收购了总部位于瑞士的 CRO Biogenesis，以扩大其在临床前活动方面的能力。

CRO 体内肿瘤市场报告亮点

实体癌领域在 2022 年占了 46.9% 的重要收入份额。 全球范围内癌症发病率的上升以及 WHO 等全球组织对分析其患病率、致病因子和治疗方案的兴趣日益浓厚，这些都在推动研究和开发。

在基于实体瘤的模型中，患者来源的异种移植物预计在预测期内实现最快的复合年增长率 8.9%。

到 2022 年，北美将占 49.6% 的最大份额，由于该地区可获得的资金前景看好，美国将做出重大贡献。 这刺激了研究活动。 大型製药和生命科学公司凭藉其在该地区的稳固地位继续推动市场增长。

亚太地区预计在预测期内实现最快的复合年增长率。 这是因为许多新兴国家正在亚太地区投资，监管机构正在根据全球平台进行各种修改以改变临床试验评估标准。

内容

第一章研究方法论

  • 市场细分和范围
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析（模型 1）
    • 批量价格分析（模型 2）
  • 二级信息列表
  • 主要信息列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场展望

第 3 章 CRO 体内肿瘤市场：变量、趋势和范围

  • 细分市场展望
  • 市场动态
    • 市场驱动因素分析
      • 缩短上市时间
      • 经济效率
      • 增加合併与协作
      • 增加研发活动的外包
    • 市场製约因素分析
      • CRO 质量问题
      • 存在合适的替代品
  • 肿瘤学体内 CRO 市场分析工具
    • 波特的五力分析
    • PESTEL 分析

第 4 章 CRO 中的体内肿瘤市场：适应症估计和趋势分析

  • 基于肿瘤的体内 CRO 市场：适应症波动分析
  • 血癌
  • 实体瘤
  • 其他

第 5 章 CRO 体内肿瘤市场：估计和趋势分析

  • 2022 年和 2030 年各地区基于肿瘤的体内 CRO 市场份额
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
  • 多边环境协定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第六章竞争格局

  • 战略框架
  • 公司简介
    • 查尔斯河实验室 (CRL)
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • ICON 有限公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Thermo Fisher Scientific Inc.
      • 公司简介
      • 财务业绩
      • 服务基准
      • 战略举措
    • 欧陆科学
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Taconic 生物科学
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 中冠生物科学
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 实验室公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 药明康德
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • EVOTEC
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 杰克逊实验室
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
Product Code: GVR-1-68038-859-6

Oncology Based In-vivo CRO Market Growth & Trends:

The global oncology based in-vivo CRO market size is expected to reach USD 2.3 billion by 2030 and is expected to expand at 8.2% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Increase in outsourcing of R&D activities, high demand for advanced medicines and implementation of international standards by CROs are key factors driving the market growth.

Furthermore, the pressure from the increasing competition due to patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology-based in-vivo CRO industry may witness lucrative growth over the forecast period.

Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs to perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharma companies seeking to make an entry into a new market. Big pharma companies such as Pfizer and GlaxoSmithKline partner with local CMOs and CROs which has proven to be successful in enabling foreign companies to achieve marketing, regulatory, and manufacturing goals in emerging economies.

Furthermore, an increase in the number of mergers and collaborations in this industry is expected to expand the market in the coming years. For instance, in January 2023, Bruker an analytical solutions company acquired a preclinical Switzerland-based CRO Biogenesis to expand its capabilities in preclinical activities.

Oncology Based In-vivo CRO Market Report Highlights:

  • Solid tumors segment accounted for a significant revenue share of 46.9% in 2022. The increasing incidence of cancer across the globe and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
  • Based on solid tumor-based model, patient-derived xenograft is anticipated to register the fastest CAGR of 8.9% during the forecast period
  • North America accounted for the largest share of 49.6% in 2022, with the major contributions from the U.S., thanks to promising funding available in the region. This has boosted the research activities. Major pharmaceutical and life sciences companies continue to drive market growth with their established presence in the region
  • Asia Pacific is anticipated to register the fastest CAGR growth during the forecast period, owing to many developed countries investing in Asia Pacific regions and owing to the various amendments made by the regulatory market to change the clinical trials evaluation standards according to the global platform

Table of Content

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Regional Scope
    • 1.1.2 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.2 Volume Price Analysis (Model 2)
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Oncology-Based In-vivo CRO Market: Variables, Trends, & Scope

  • 3.1 Segment Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Accelerating the time to market
      • 3.2.1.2 Economic efficiency
      • 3.2.1.3 Increasing mergers and collaborations
      • 3.2.1.4 Increasing outsourcing of R&D Activities
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Quality issues with CRO
      • 3.2.2.2 Presence of suitable alternative
  • 3.3 Oncology In-vivo CRO Market Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 PESTEL Analysis

Chapter 4 Oncology-Based in-vivo CRO Market: Indication Estimates & Trend Analysis

  • 4.1 Oncology-Based in-vivo CRO Market: Indication Movement Analysis
  • 4.2 Blood cancer
    • 4.2.1 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3 Solid tumors
    • 4.3.1 Solid tumors market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4 Others
    • 4.4.1 Other market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Oncology-Based in-vivo CRO Market: Regional Estimates & Trend Analysis, by Indication

  • 5.1 Oncology-Based in-vivo CRO Market Share by Region, 2022 & 2030
  • 5.2 North America
    • 5.2.1 North America Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.2.2 U.S.
      • 5.2.2.1 U.S. Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.3.2 U.K.
      • 5.3.2.1 U.K. Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Germany Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.4 France
      • 5.3.4.1 France Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.5 Italy
      • 5.3.5.1 Italy Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.6 Spain
      • 5.3.6.1 Spain Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.7 Norway
      • 5.3.7.1 Norway Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.8 Sweden
      • 5.3.8.1 Sweden Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.3.9 Denmark
      • 5.3.9.1 Denmark Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.4.2 Japan
      • 5.4.2.1 Japan Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.3 China
      • 5.4.3.1 China Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.4 India
      • 5.4.4.1 India Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.5 Australia
      • 5.4.5.1 Australia Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.6 Thailand
      • 5.4.6.1 Thailand Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.4.7 South Korea
      • 5.4.7.1 South Korea Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Latin America Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.5.3 Argentina
      • 5.5.3.1 Argentina Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.5.4 Mexico
      • 5.5.4.1 Mexico Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
  • 5.6 MEA
    • 5.6.1 MEA Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.6.3 Saudi Arabia
      • 5.6.3.1 Saudi Arabia Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.6.4 UAE
      • 5.6.4.1 UAE Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
    • 5.6.5 Kuwait
      • 5.6.5.1 Kuwait Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)

Chapter 6 Competitive Landscape

  • 6.1 Strategy Framework
  • 6.2 Company Profiles
    • 6.2.1 Charles River Laboratory (CRL)
      • 6.2.1.1 Company overview
      • 6.2.1.2 Financial performance
      • 6.2.1.3 Product benchmarking
      • 6.2.1.4 Strategic initiatives
    • 6.2.2 ICON Plc
      • 6.2.2.1 Company overview
      • 6.2.2.2 Financial performance
      • 6.2.2.3 Product benchmarking
      • 6.2.2.4 Strategic initiatives
    • 6.2.3 Thermo Fisher Scientific Inc.
      • 6.2.3.1 Company overview
      • 6.2.3.2 Financial performance
      • 6.2.3.3 Service benchmarking
      • 6.2.3.4 Strategic initiatives
    • 6.2.4 Eurofins Scientific
      • 6.2.4.1 Company overview
      • 6.2.4.2 Financial performance
      • 6.2.4.3 Product benchmarking
      • 6.2.4.4 Strategic initiatives
    • 6.2.5 Taconic Biosciences
      • 6.2.5.1 Company overview
      • 6.2.5.2 Financial performance
      • 6.2.5.4 Product benchmarking
      • 6.2.5.5 Strategic initiatives
    • 6.2.6 Crown Bioscience
      • 6.2.6.1 Company overview
      • 6.2.6.2 Financial performance
      • 6.2.6.3 Product benchmarking
      • 6.2.6.4 Strategic initiatives
    • 6.2.7 Lab Corp
      • 6.2.7.1 Company overview
      • 6.2.7.2 Financial performance
      • 6.2.7.3 Product benchmarking
      • 6.2.7.4 Strategic initiatives
    • 6.2.8 WuXi AppTec
      • 6.2.8.1 Company overview
      • 6.2.8.2 Financial performance
      • 6.2.8.4 Product benchmarking
      • 6.2.8.5 Strategic Initiatives
    • 6.2.9 EVOTEC
      • 6.2.9.1 Company overview
      • 6.2.9.2 Financial performance
      • 6.2.9.3 Product benchmarking
      • 6.2.9.4 Strategic initiatives
    • 6.2.10 The Jackson Laboratory
      • 6.2.10.1 Company overview
      • 6.2.10.2 Financial performance
      • 6.2.10.4 Product benchmarking
      • 6.2.10.5 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market summary
  • Fig. 2 Market trends & outlook
  • Fig. 3 Market segmentation & scope
  • Fig. 4 Market driver relevance analysis (Current & future impact)
  • Fig. 5 Pharmaceutical R&D spending, 2007 - 2012 (USD Billion)
  • Fig. 6 Market restraint relevance analysis (Current & future impact)
  • Fig. 7 Penetration & growth prospect mapping
  • Fig. 8 SWOT Analysis, By Factor (political & legal, economic and social)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 Oncology-Based in-vivo CRO market indication outlook key takeaways
  • Fig. 11 Oncology-Based in-vivo CRO market: Indication movement analysis
  • Fig. 12 Global blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 13 Global syngeneic model-based blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 14 Global PDX model-based blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 15 Global xenograft-based blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 16 Global solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 17 Global syngeneic model-based solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 18 Global PDX model-based solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 19 Global xenograft-based solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 20 Global other cancers market, 2018 - 2030 (USD Million)
  • Fig. 21 Global syngeneic model-based other cancers market, 2018 - 2030 (USD Million)
  • Fig. 22 Global PDX model-based other cancers market, 2018 - 2030 (USD Million)
  • Fig. 23 Global xenograft-based other cancers market, 2018 - 2030 (USD Million)
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 Regional outlook, 2022 & 2030
  • Fig. 26 North America Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 29 Europe in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 30 U.K. Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 31 Germany Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 32 France Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 33 Italy Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 34 Spain Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 35 Norway Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 36 Sweden Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 38 Asia Pacific Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 39 Japan oncology-based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 40 China oncology-based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 41 India Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 42 Australia Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 43 Thailand Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 45 Latin America Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 46 Brazil Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 47 Argentina Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 49 MEA Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)